Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Invivyd's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Invivyd's regulatory disclosures and financial reporting.
Invivyd, Inc. filed a current report describing several disclosures made on August 14, 2025. The company issued a press release with its financial results for the quarter ended June 30, 2025 and recent business highlights, which is included as Exhibit 99.1.
Invivyd also released a separate press release titled “Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19,” filed as Exhibit 99.2. In addition, the company posted an updated corporate presentation on its website, furnished as Exhibit 99.3.
This Schedule 13G/A discloses that Maverick Capital, Ltd., Maverick Capital Management, LLC and Lee S. Ainslie III report beneficial ownership of 10,229,118 shares of Invivyd, Inc., representing 8.5% of the 119,961,445 outstanding shares reported as of May 1, 2025. The filing identifies the shares as held for Maverick clients across five funds: Maverick Fund USA, Ltd. (2,253,369), Maverick Fund II, Ltd. (2,210,410), Maverick Long Enhanced Fund, Ltd. (2,419,202), Maverick HP, L.P. (2,139,246) and Maverick Long Fund, Ltd. (1,206,891).
Each reporting person states shared voting and dispositive power over these shares and no sole voting or dispositive power. The document is filed as a Schedule 13G (Amendment No. 2) and includes a certification that the securities were not acquired to change or influence control of the issuer. The filing lists Maverick's Dallas, TX address and Mr. Ainslie's West Palm Beach, FL address and is signed on 08/14/2025.
Invivyd, Inc. (Nasdaq: IVVD) filed an 8-K to disclose that, on July 2, 2025, it issued a press release announcing the formation of the SPEAR (Spike Protein Elimination and Recovery) Study Group. The collaboration brings Invivyd together with leading researchers to evaluate the effects of the company’s monoclonal antibody therapy on two patient populations: 1) individuals suffering from Long COVID and 2) those experiencing COVID-19 post-vaccination syndrome.
The filing contains no financial results, trial data, or guidance. Instead, it simply furnishes the press release as Exhibit 99.1 under Item 8.01 (Other Events) and lists customary exhibit and signature information.
Invivyd (Nasdaq: IVVD) filed an 8-K under Item 8.01 to furnish a press release dated 26 June 2025.
The release reports positive full Phase 1/2 clinical data for VYD2311, a next-generation COVID-19 monoclonal antibody being pursued for both non-vaccine prophylaxis and treatment of active infection.
The document attaches the press release as Exhibit 99.1; no financial statements, guidance changes, or other material corporate actions were disclosed.